September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
January 2022 in “Asian journal of Current Research in Clinical Cancer” Some dibenzo compounds might help treat cancer with fewer side effects.
July 2025 in “Frontiers in Medicine” Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
1 citations
,
September 2001 in “PubMed” ONO-3403 effectively reduces mouse skin tumor growth without side effects.
November 2025 in “Journal of Cutaneous Medicine and Surgery” JAK inhibitors are effective and safe for treating severe alopecia areata.
129 citations
,
January 2004 in “Journal of medicinal chemistry” Researchers developed new compounds that target the androgen receptor effectively with fewer side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
7 citations
,
December 2013 in “The Journal of Dermatology” A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.
23 citations
,
January 2012 in “International Food Research Journal” Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
7 citations
,
January 2009 in “BMJ Case Reports” Gefitinib can cause slower, finer, brittle, and curly scalp hair.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
11 citations
,
June 2016 in “European Journal of Medicinal Chemistry” Compounds 6f and 6g effectively stop prostate cancer cell growth without harming healthy cells.
March 2023 in “Jurnal Ilmiah Medicamento” The hair tonic from Usada Bali plants increased hair growth without irritating the skin.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
1 citations
,
November 2024 in “Blood” PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.
3 citations
,
October 2024 in “Frontiers in Pharmacology” Compounds from Pterocarpus indicus may help treat benign prostatic hyperplasia by stopping cell growth.
October 2020 in “Der Hautarzt” Tofacitinib helped regrow hair in a woman with alopecia areata.
6 citations
,
March 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective for long-term treatment of severe alopecia areata.
36 citations
,
October 2019 in “Cell Proliferation” Tryptanthrin effectively suppresses non-melanoma skin cancer and is safe for normal skin.
August 2022 in “Journal of Investigative Dermatology” Baricitinib reduces inflammation and mitochondrial damage in skin cells.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
40 citations
,
January 2017 in “Intestinal Research” Genotyping for NUDT15 p.Arg139Cys can help predict thiopurine side effects in Japanese IBD patients.
1 citations
,
October 2025 in “Gels” Nanogels with hydrophobic modifications improve oral drug delivery for intestinal disease treatment.
January 2026 in “Elsevier eBooks” 13 citations
,
June 2008 in “International Journal of Dermatology” Sorafenib can cause a unique skin reaction.
Topical GT20029 effectively promotes hair regrowth and is well-tolerated for treating androgenetic alopecia.